AI / ML Innovations Stock Price, News & Analysis

AI/ML Innovations Inc. announced a License Agreement with MedWatch Technologies, Inc. to utilize patented health management technology and AI software for diabetes monitoring solutions. MedWatch will pay Health Gauge an annual fee of US$120,000 plus a 2% royalty on gross sales. With diabetes-related medical costs in the US at $327 billion annually, the partnership aims to improve patient outcomes through non-invasive monitoring tools. The agreement spans an initial term of 7 years, with a US$2 million termination fee.

AI/ML Innovations Inc. announced a license agreement with MedWatch Technologies for its patented health management technology, targeting the $327 billion US diabetes market. MedWatch will pay an annual fee of US$120,000 plus a 2% royalty on gross sales, projected to be US$5.00 to US$8.00 per device. The agreement has an initial term of 7 years with automatic renewals and includes a US$2 million early termination fee. This strategic partnership aims to enhance diabetes management through innovative blood glucose monitoring solutions.

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) has completed a non-brokered private placement, issuing 4 million units at $0.15 per unit, resulting in $600,000 in gross proceeds. Each unit consists of one common share and one share purchase warrant, exercisable at $0.20 for 12 months. The funds will support platform deployment with healthcare clients and general operating expenses. The company incurred $25,337.81 in finder's fees for this offering.

AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced that its subsidiary, Tech2Heal SAS, has been selected as a founding participant in the PariSanté Health Tech Campus in Paris, France. This initiative aims to foster collaboration among leading health-tech entities to enhance research and innovation in e-health. Tech2Heal's recognition reflects its leadership in digital mental healthcare. The campus includes prominent players like Inserm and Health Data Hub, providing Tech2Heal access to a rich ecosystem of expertise to strengthen its healthcare solutions.

AI/ML Innovations Inc. announces that its subsidiary, Health Gauge, has received a patent (US Patent No. 11183303) for its wearable health monitoring technology. This technology utilizes machine learning to enhance the accuracy of health metrics such as blood pressure, enabling users to achieve personal health goals. Key features include predictive health analysis and behavioral insights based on data from various bio-signals. The patent solidifies Health Gauge's position in the AI-supported telemedicine field, aimed at improving health monitoring during and beyond the pandemic.

AI/ML Innovations (CSE:AIML)(OTCQB:AIMLF) announces a SaaS licensing agreement between its subsidiary Health Gauge and Rapid Test & Trace Canada (RTTC) for a COVID-19 testing solution. Health Gauge will earn up to $2.50 per test plus additional fees. The contract grants RTTC exclusive rights in Canada, the U.S., Mexico, Australia, and the U.K., contingent upon achieving a minimum of 50,000 tests monthly per country by March 1, 2022. Deployment is expected within 30 days. This agreement is projected to generate substantial recurring revenue for Health Gauge.

AI/ML Innovations Inc. has announced its first SaaS licensing contract through its subsidiary, Health Gauge, with Rapid Test & Trace Canada (RTTC) for a COVID testing solution. The agreement allows Health Gauge to receive up to $2.50 per test, with a minimum of 50,000 tests per month required across five countries by March 2022. Deployment of the solution is anticipated within 30 days. The partnership aims to enhance COVID testing verification for RTTC's large corporate clientele.

AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) has successfully completed its Warrant Early Exercise Incentive Program, resulting in the exercise of 2,288,000 warrants. This has led to the issuance of 1,144,000 common shares and raised $572,000 in working capital. The company is focused on advancing Artificial Intelligence and Machine Learning technologies, particularly in digital health. Through strategic partnerships, it aims to enhance healthcare management solutions.

AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF) announced its subsidiary AI Rx Inc. is ready to launch its Tech2Heal product portfolio in the US, focusing on digital behavioral health. To aid market entry, AIML retained Oxygen Enterprises Inc. to develop a market strategy and facilitate key partnerships. AIML will compensate Oxygen with CDN $80,000, 100,000 shares, and 100,000 stock options. The company's strategy leverages AI and machine learning technologies to advance healthcare solutions, aiming for significant growth in the digital health sector.